Connection

GUNAR K ZAGARS to Male

This is a "connection" page, showing publications GUNAR K ZAGARS has written about Male.
Connection Strength

0.466
  1. The role of adjuvant radiotherapy in the local management of desmoplastic melanoma. Cancer. 2014 May 01; 120(9):1361-8.
    View in: PubMed
    Score: 0.014
  2. Dermatofibrosarcoma protuberans: long-term outcomes of 53 patients treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys. 2013 Jul 01; 86(3):585-90.
    View in: PubMed
    Score: 0.013
  3. Role of postoperative irradiation for patients with bilateral cervical nodal metastases from cutaneous melanoma: a critical assessment. Head Neck. 2010 Jun; 32(6):708-13.
    View in: PubMed
    Score: 0.011
  4. Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys. 2009 Apr 01; 73(5):1376-82.
    View in: PubMed
    Score: 0.010
  5. Management of locally recurrent soft-tissue sarcoma after prior surgery and radiation therapy. Int J Radiat Oncol Biol Phys. 2007 Mar 15; 67(4):1124-9.
    View in: PubMed
    Score: 0.009
  6. Combined-modality therapy for patients with regional nodal metastases from melanoma. Int J Radiat Oncol Biol Phys. 2006 Jan 01; 64(1):106-13.
    View in: PubMed
    Score: 0.008
  7. Mortality after cure of testicular seminoma. J Clin Oncol. 2004 Feb 15; 22(4):640-7.
    View in: PubMed
    Score: 0.007
  8. Prognostic factors for disease-specific survival after first relapse of soft-tissue sarcoma: analysis of 402 patients with disease relapse after initial conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys. 2003 Nov 01; 57(3):739-47.
    View in: PubMed
    Score: 0.007
  9. Significance of dose in postoperative radiotherapy for soft tissue sarcoma. Int J Radiat Oncol Biol Phys. 2003 Jun 01; 56(2):473-81.
    View in: PubMed
    Score: 0.007
  10. Preoperative vs. postoperative radiation therapy for soft tissue sarcoma: a retrospective comparative evaluation of disease outcome. Int J Radiat Oncol Biol Phys. 2003 Jun 01; 56(2):482-8.
    View in: PubMed
    Score: 0.007
  11. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer. 2003 May 15; 97(10):2530-43.
    View in: PubMed
    Score: 0.007
  12. Surgical margins and reresection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy. Cancer. 2003 May 15; 97(10):2544-53.
    View in: PubMed
    Score: 0.007
  13. Sequencing radiotherapy for soft tissue sarcoma when re-resection is planned. Int J Radiat Oncol Biol Phys. 2003 May 01; 56(1):21-7.
    View in: PubMed
    Score: 0.007
  14. Impact of androgen deprivation therapy on survival in men treated with radiation for prostate cancer. Urology. 2002 Sep; 60(3 Suppl 1):22-30; discussion 30-1.
    View in: PubMed
    Score: 0.006
  15. Radiotherapy for stage II testicular seminoma. Int J Radiat Oncol Biol Phys. 2001 Nov 01; 51(3):643-9.
    View in: PubMed
    Score: 0.006
  16. Epithelioid sarcoma: results of conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys. 2001 Oct 01; 51(2):384-91.
    View in: PubMed
    Score: 0.006
  17. Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer. Urology. 2001 Aug; 58(2):233-9.
    View in: PubMed
    Score: 0.006
  18. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1999 Jul 01; 44(4):809-19.
    View in: PubMed
    Score: 0.005
  19. Relationship of ultrasound staging and bilateral biopsy positivity to outcome in stage T1c prostate cancer treated with radiotherapy. Urology. 1998 Oct; 52(4):647-52.
    View in: PubMed
    Score: 0.005
  20. Prostate cancer in African-American men: outcome following radiation therapy with or without adjuvant androgen ablation. Int J Radiat Oncol Biol Phys. 1998 Oct 01; 42(3):517-23.
    View in: PubMed
    Score: 0.005
  21. Regarding Zagars and Pollack. Int J Radiat Oncol Biol Phys. 1998 Jul 01; 41(4):973-4.
    View in: PubMed
    Score: 0.005
  22. Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology. 1998 Jun; 51(6):991-7.
    View in: PubMed
    Score: 0.005
  23. Malignant Peripheral Nerve Sheath Tumors: A Single Institution's Experience Using Combined Surgery and Radiation Therapy. Am J Clin Oncol. 2018 05; 41(5):465-470.
    View in: PubMed
    Score: 0.005
  24. Androgen ablation in addition to radiation therapy for prostate cancer: is there true benefit? Semin Radiat Oncol. 1998 Apr; 8(2):95-106.
    View in: PubMed
    Score: 0.005
  25. External beam radiotherapy for stage T1/T2 prostate cancer: how does it stack up? Urology. 1998 Feb; 51(2):258-64.
    View in: PubMed
    Score: 0.005
  26. Soft Tissue Solitary Fibrous Tumor: Combined Surgery and Radiation Therapy Results in Excellent Local Control. Am J Clin Oncol. 2018 Jan; 41(1):81-85.
    View in: PubMed
    Score: 0.005
  27. External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Phys. 1997 Dec 01; 39(5):1011-8.
    View in: PubMed
    Score: 0.005
  28. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol. 1997 Sep; 44(3):213-21.
    View in: PubMed
    Score: 0.004
  29. Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation. Cancer. 1997 Aug 15; 80(4):764-75.
    View in: PubMed
    Score: 0.004
  30. Serum testosterone levels after external beam radiation for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 1997 Aug 01; 39(1):85-9.
    View in: PubMed
    Score: 0.004
  31. Prostate-specific antigen cancer volume: a significant prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy. Int J Radiat Oncol Biol Phys. 1997 May 01; 38(2):327-33.
    View in: PubMed
    Score: 0.004
  32. Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era. Cancer. 1997 Apr 01; 79(7):1370-80.
    View in: PubMed
    Score: 0.004
  33. Serum testosterone--a significant determinant of metastatic relapse for irradiated localized prostate cancer. Urology. 1997 Mar; 49(3):327-34.
    View in: PubMed
    Score: 0.004
  34. Liposarcoma: outcome and prognostic factors following conservation surgery and radiation therapy. Int J Radiat Oncol Biol Phys. 1996 Sep 01; 36(2):311-9.
    View in: PubMed
    Score: 0.004
  35. Treatment-related fractures after combined modality therapy for soft tissue sarcomas of the proximal lower extremity: Can the risk be mitigated? Pract Radiat Oncol. 2016 May-Jun; 6(3):194-200.
    View in: PubMed
    Score: 0.004
  36. Radiotherapy vs. surgery for prostate cancer: an age old question. Int J Radiat Oncol Biol Phys. 1996 May 01; 35(2):407-9.
    View in: PubMed
    Score: 0.004
  37. Malignant fibrous histiocytoma: outcome and prognostic factors following conservation surgery and radiotherapy. Int J Radiat Oncol Biol Phys. 1996 Mar 15; 34(5):983-94.
    View in: PubMed
    Score: 0.004
  38. Radiotherapy for regionally localized hormone refractory prostate cancer. Int J Radiat Oncol Biol Phys. 1995 Nov 01; 33(4):907-12.
    View in: PubMed
    Score: 0.004
  39. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen. Int J Radiat Oncol Biol Phys. 1995 Aug 30; 33(1):23-35.
    View in: PubMed
    Score: 0.004
  40. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 1995 May 15; 32(2):293-306.
    View in: PubMed
    Score: 0.004
  41. Combined Modality Management of Retroperitoneal Sarcomas: A Single-Institution Series of 121 Patients. Int J Radiat Oncol Biol Phys. 2015 Sep 01; 93(1):158-65.
    View in: PubMed
    Score: 0.004
  42. The source of pretreatment serum prostate-specific antigen in clinically localized prostate cancer--T, N, or M? Int J Radiat Oncol Biol Phys. 1995 Apr 30; 32(1):21-32.
    View in: PubMed
    Score: 0.004
  43. Combined Limb-Sparing Surgery and Radiation Therapy to Treat Sarcomas of the Hands and Feet: Long-Term Cancer Outcomes and Morbidity. Int J Radiat Oncol Biol Phys. 2015 Aug 01; 92(5):1060-1068.
    View in: PubMed
    Score: 0.004
  44. Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome. Urology. 1995 Mar; 45(3):476-83.
    View in: PubMed
    Score: 0.004
  45. Gleason grade and other prognostic factors--response to Drs. Hammond and Grignon. Int J Radiat Oncol Biol Phys. 1995 Jan 15; 31(2):435.
    View in: PubMed
    Score: 0.004
  46. The prognostic importance of Gleason grade in prostatic adenocarcinoma: a long-term follow-up study of 648 patients treated with radiation therapy. Int J Radiat Oncol Biol Phys. 1995 Jan 15; 31(2):237-45.
    View in: PubMed
    Score: 0.004
  47. Influence of radiotherapy on node-positive prostate cancer treated with androgen ablation. Int J Radiat Oncol Biol Phys. 1995 Jan 01; 31(1):13-9.
    View in: PubMed
    Score: 0.004
  48. Neutron therapy in prostate cancer--is the therapeutic ratio improved? Int J Radiat Oncol Biol Phys. 1995 Jan 01; 31(1):204-5.
    View in: PubMed
    Score: 0.004
  49. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy. J Urol. 1994 Nov; 152(5 Pt 2):1786-91.
    View in: PubMed
    Score: 0.004
  50. Synovial sarcoma outcome following conservation surgery and radiotherapy. Radiother Oncol. 1994 Oct; 33(1):23-30.
    View in: PubMed
    Score: 0.004
  51. Early androgen ablation for stage D1 (N1 to N3, M0) prostate cancer: prognostic variables and outcome. J Urol. 1994 May; 151(5):1330-3.
    View in: PubMed
    Score: 0.004
  52. The T classification of clinically localized prostate cancer. An appraisal based on disease outcome after radiation therapy. Cancer. 1994 Apr 01; 73(7):1904-12.
    View in: PubMed
    Score: 0.004
  53. The prognostic significance of DNA ploidy in clinically localized prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys. 1994 Mar 01; 28(4):821-8.
    View in: PubMed
    Score: 0.003
  54. The serum prostate-specific antigen level three months after radiotherapy for prostate cancer: an early indicator of response to treatment. Radiother Oncol. 1994 Feb; 30(2):121-7.
    View in: PubMed
    Score: 0.003
  55. Serum PSA as a tumor marker for patients undergoing definitive radiation therapy. Urol Clin North Am. 1993 Nov; 20(4):737-47.
    View in: PubMed
    Score: 0.003
  56. Prognostic factors in prostate cancer. Analysis of 874 patients treated with radiation therapy. Cancer. 1993 Sep 01; 72(5):1709-25.
    View in: PubMed
    Score: 0.003
  57. The prognostic significance of a single serum prostate-specific antigen value beyond six months after radiation therapy for adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1993 Sep 01; 27(1):39-45.
    View in: PubMed
    Score: 0.003
  58. The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer. Cancer. 1993 Aug 01; 72(3):832-42.
    View in: PubMed
    Score: 0.003
  59. Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapy. Cancer. 1993 Jul 15; 72(2):538-48.
    View in: PubMed
    Score: 0.003
  60. Post-orchiectomy radiotherapy for stages I and II testicular seminoma. Int J Radiat Oncol Biol Phys. 1993 Jun 15; 26(3):381-90.
    View in: PubMed
    Score: 0.003
  61. Radiotherapy versus surgery for stage C prostate cancer. Urology. 1993 Jun; 41(6):605.
    View in: PubMed
    Score: 0.003
  62. In regard to Pollack et al., prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. IJROBP 2002;53:1097-1105. Int J Radiat Oncol Biol Phys. 2003 Apr 01; 55(5):1461; author reply 1461-2.
    View in: PubMed
    Score: 0.003
  63. A commentary on dose escalation and bNED in prostate cancer. Int J Radiat Oncol Biol Phys. 2003 Mar 15; 55(4):1151; author reply 1151-2.
    View in: PubMed
    Score: 0.003
  64. Stage I testicular seminoma following orchidectomy--to treat or not to treat. Eur J Cancer. 1993; 29A(14):1923-4.
    View in: PubMed
    Score: 0.003
  65. A population-based study of the quality of care in the diagnosis of large (=5 cm) soft tissue sarcomas. Am J Clin Oncol. 2012 Oct; 35(5):455-61.
    View in: PubMed
    Score: 0.003
  66. Treatment of seminoma arising in cryptorchid testes. Int J Radiat Oncol Biol Phys. 1992; 24(1):153-9.
    View in: PubMed
    Score: 0.003
  67. Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy. Int J Radiat Oncol Biol Phys. 1992; 23(1):47-53.
    View in: PubMed
    Score: 0.003
  68. The influence of local control on metastatic dissemination of prostate cancer treated by external beam megavoltage radiation therapy. Cancer. 1991 Dec 01; 68(11):2370-7.
    View in: PubMed
    Score: 0.003
  69. Sphincter-sparing local excision and hypofractionated radiation therapy for anorectal melanoma: a 20-year experience. Cancer. 2011 Oct 15; 117(20):4747-55.
    View in: PubMed
    Score: 0.003
  70. Prostate-specific antigen and external beam radiation therapy in prostate cancer. Cancer. 1991 Jan 15; 67(2):412-20.
    View in: PubMed
    Score: 0.003
  71. Outcomes after definitive treatment for cutaneous angiosarcoma of the face and scalp. Head Neck. 2011 May; 33(5):661-7.
    View in: PubMed
    Score: 0.003
  72. Preoperative irradiation and radical cystectomy for stages T2 and T3 squamous cell carcinoma of the bladder. J Urol. 1990 Jan; 143(1):37-40.
    View in: PubMed
    Score: 0.003
  73. Osteosarcoma of the jaw/craniofacial region: outcomes after multimodality treatment. Cancer. 2009 Jul 15; 115(14):3262-70.
    View in: PubMed
    Score: 0.003
  74. The influence of pelvic node irradiation on prognosis. Int J Radiat Oncol Biol Phys. 1989 Mar; 16(3):882.
    View in: PubMed
    Score: 0.002
  75. Mortality after cure of soft-tissue sarcoma treated with conservation surgery and radiotherapy. Cancer. 2008 Jul 15; 113(2):411-8.
    View in: PubMed
    Score: 0.002
  76. Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study. Int J Radiat Oncol Biol Phys. 1988 Jun; 14(6):1085-91.
    View in: PubMed
    Score: 0.002
  77. The role of radiation therapy in stages A2 and B adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1988 Apr; 14(4):701-9.
    View in: PubMed
    Score: 0.002
  78. Long-term outcomes for desmoid tumors treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2008 Jun 01; 71(2):441-7.
    View in: PubMed
    Score: 0.002
  79. Seminoma with bulky abdominal disease. Int J Radiat Oncol Biol Phys. 1988 Feb; 14(2):395-7.
    View in: PubMed
    Score: 0.002
  80. Testicular seminoma: the M. D. Anderson experience. An analysis of pathological and patient characteristics, and treatment recommendations. J Urol. 1988 Feb; 139(2):311-4.
    View in: PubMed
    Score: 0.002
  81. Stage C adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiation. Cancer. 1987 Oct 01; 60(7):1489-99.
    View in: PubMed
    Score: 0.002
  82. Long-term results of prospective trial of surgery alone with selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomas. Ann Surg. 2007 Oct; 246(4):675-81; discussion 681-2.
    View in: PubMed
    Score: 0.002
  83. Excellent local control rates and distinctive patterns of failure in myxoid liposarcoma treated with conservation surgery and radiotherapy. Int J Radiat Oncol Biol Phys. 2008 Mar 01; 70(3):760-5.
    View in: PubMed
    Score: 0.002
  84. Long-term outcomes for synovial sarcoma treated with conservation surgery and radiotherapy. Int J Radiat Oncol Biol Phys. 2007 Nov 15; 69(4):1173-80.
    View in: PubMed
    Score: 0.002
  85. Stage I testicular seminoma: rationale for postorchiectomy radiation therapy. Int J Radiat Oncol Biol Phys. 1987 Feb; 13(2):155-62.
    View in: PubMed
    Score: 0.002
  86. The role of radiation in stage II testicular seminoma. Int J Radiat Oncol Biol Phys. 1987 Feb; 13(2):163-70.
    View in: PubMed
    Score: 0.002
  87. Periosteal margin in soft-tissue sarcoma. Cancer. 2007 Feb 01; 109(3):598-602.
    View in: PubMed
    Score: 0.002
  88. Complications of combined modality treatment of primary lower extremity soft-tissue sarcomas. Cancer. 2006 Nov 15; 107(10):2455-61.
    View in: PubMed
    Score: 0.002
  89. Retroperitoneal soft tissue sarcoma: an analysis of radiation and surgical treatment. Int J Radiat Oncol Biol Phys. 2007 Jan 01; 67(1):158-63.
    View in: PubMed
    Score: 0.002
  90. The effect of preoperative radiotherapy and reconstructive surgery on wound complications after resection of extremity soft-tissue sarcomas. Ann Surg Oncol. 2006 Sep; 13(9):1209-15.
    View in: PubMed
    Score: 0.002
  91. Hodgkin's disease stages IA and IIA. A long-term follow-up study on the gains achieved by modern therapy. Cancer. 1985 Oct 15; 56(8):1905-12.
    View in: PubMed
    Score: 0.002
  92. Laparotomy-staged IA versus IIA Hodgkin's disease. A comparative study with evaluation of prognostic factors for stage IIA disease. Cancer. 1985 Aug 15; 56(4):864-73.
    View in: PubMed
    Score: 0.002
  93. A critical assessment of adjuvant radiotherapy for inguinal lymph node metastases from melanoma. Ann Surg Oncol. 2004 Dec; 11(12):1079-84.
    View in: PubMed
    Score: 0.002
  94. Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas. J Clin Oncol. 2004 Aug 15; 22(16):3375-80.
    View in: PubMed
    Score: 0.002
  95. Interval between surgery and radiotherapy: effect on local control of soft tissue sarcoma. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1461-7.
    View in: PubMed
    Score: 0.002
  96. Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology. 2003 Oct; 62(4):707-13.
    View in: PubMed
    Score: 0.002
  97. Radiotherapy in the management of giant cell tumor of bone. Int J Radiat Oncol Biol Phys. 2003 Sep 01; 57(1):158-65.
    View in: PubMed
    Score: 0.002
  98. Phase I trial of preoperative concurrent doxorubicin and radiation therapy, surgical resection, and intraoperative electron-beam radiation therapy for patients with localized retroperitoneal sarcoma. J Clin Oncol. 2003 Aug 15; 21(16):3092-7.
    View in: PubMed
    Score: 0.002
  99. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x. Cancer. 2003 Apr 01; 97(7):1630-8.
    View in: PubMed
    Score: 0.002
  100. Adjuvant irradiation for cervical lymph node metastases from melanoma. Cancer. 2003 Apr 01; 97(7):1789-96.
    View in: PubMed
    Score: 0.002
  101. Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. J Clin Oncol. 2002 Dec 01; 20(23):4555-8.
    View in: PubMed
    Score: 0.002
  102. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial. Int J Radiat Oncol Biol Phys. 2002 Nov 01; 54(3):677-85.
    View in: PubMed
    Score: 0.002
  103. Surgical management of soft tissue sarcomas of the hand and foot. Cancer. 2002 Aug 15; 95(4):852-61.
    View in: PubMed
    Score: 0.002
  104. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002 Aug 01; 53(5):1097-105.
    View in: PubMed
    Score: 0.002
  105. Adult rhabdomyosarcoma: outcome following multimodality treatment. Cancer. 2002 Jul 15; 95(2):377-88.
    View in: PubMed
    Score: 0.002
  106. Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy. Clin Cancer Res. 2002 May; 8(5):1148-54.
    View in: PubMed
    Score: 0.002
  107. Extraosseous osteosarcoma: response to treatment and long-term outcome. J Clin Oncol. 2002 Jan 15; 20(2):521-7.
    View in: PubMed
    Score: 0.002
  108. Spermatic cord sarcoma: outcome, patterns of failure and management. J Urol. 2001 Oct; 166(4):1306-10.
    View in: PubMed
    Score: 0.001
  109. Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma. Cancer. 2001 Sep 15; 92(6):1550-5.
    View in: PubMed
    Score: 0.001
  110. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol. 2000 Dec 01; 18(23):3904-11.
    View in: PubMed
    Score: 0.001
  111. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys. 2000 Oct 01; 48(3):635-42.
    View in: PubMed
    Score: 0.001
  112. Minisatellite mutation frequency in human sperm following radiotherapy. Mutat Res. 2000 Sep 20; 453(1):67-75.
    View in: PubMed
    Score: 0.001
  113. The early supra-additive apoptotic response of R3327-G prostate tumors to androgen ablation and radiation is not sustained with multiple fractions. Int J Radiat Oncol Biol Phys. 2000 Jan 01; 46(1):153-8.
    View in: PubMed
    Score: 0.001
  114. Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy. Prostate. 1999 Nov 01; 41(3):166-72.
    View in: PubMed
    Score: 0.001
  115. Long-term outcome of patients with American Joint Committee on Cancer stage IIB extremity soft tissue sarcomas. J Clin Oncol. 1999 Sep; 17(9):2772-80.
    View in: PubMed
    Score: 0.001
  116. Transrectal ultrasound for staging prostate carcinoma prior to radiation therapy: an evaluation based on disease outcome. Cancer. 1999 Apr 01; 85(7):1577-85.
    View in: PubMed
    Score: 0.001
  117. Prostate cancer treatment with radiotherapy: maturing methods that minimize morbidity. Semin Oncol. 1999 Apr; 26(2):150-61.
    View in: PubMed
    Score: 0.001
  118. Familial prostate cancer: outcome following radiation therapy with or without adjuvant androgen ablation. Int J Radiat Oncol Biol Phys. 1999 Jan 15; 43(2):379-83.
    View in: PubMed
    Score: 0.001
  119. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol. 1999 Jan; 17(1):158-67.
    View in: PubMed
    Score: 0.001
  120. Radiation therapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys. 1998 Dec 01; 42(5):1007-14.
    View in: PubMed
    Score: 0.001
  121. Preoperative vs. postoperative radiotherapy in the treatment of soft tissue sarcomas: a matter of presentation. Int J Radiat Oncol Biol Phys. 1998 Oct 01; 42(3):563-72.
    View in: PubMed
    Score: 0.001
  122. Prostate target volume variations during a course of radiotherapy. Int J Radiat Oncol Biol Phys. 1998 Oct 01; 42(3):661-72.
    View in: PubMed
    Score: 0.001
  123. The role of radiation therapy in the management of dermatofibrosarcoma protuberans. Int J Radiat Oncol Biol Phys. 1998 Mar 01; 40(4):823-7.
    View in: PubMed
    Score: 0.001
  124. Retinoblastoma protein expression and radiation response in muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys. 1997 Oct 01; 39(3):687-95.
    View in: PubMed
    Score: 0.001
  125. Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer. Clin Cancer Res. 1997 Oct; 3(10):1823-9.
    View in: PubMed
    Score: 0.001
  126. Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Int J Radiat Oncol Biol Phys. 1997 Jul 15; 38(5):1071-7.
    View in: PubMed
    Score: 0.001
  127. Quiescence in R3327-G rat prostate tumors after androgen ablation. Cancer Res. 1997 Jun 15; 57(12):2493-500.
    View in: PubMed
    Score: 0.001
  128. The significance of DNA-ploidy and S-phase fraction in node-positive (stage D1) prostate cancer treated with androgen ablation. Prostate. 1997 Apr 01; 31(1):21-8.
    View in: PubMed
    Score: 0.001
  129. Significance of downstaging in muscle-invasive bladder cancer treated with preoperative radiotherapy. Int J Radiat Oncol Biol Phys. 1997 Jan 01; 37(1):41-9.
    View in: PubMed
    Score: 0.001
  130. Apoptosis and downstaging after preoperative radiotherapy for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys. 1996 May 01; 35(2):281-7.
    View in: PubMed
    Score: 0.001
  131. Prostate specific antigen density as a prognostic factor for patients with prostate carcinoma treated with radiotherapy. Cancer. 1996 Apr 15; 77(8):1515-23.
    View in: PubMed
    Score: 0.001
  132. Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy. Urology. 1996 Mar; 47(3):305-10.
    View in: PubMed
    Score: 0.001
  133. Conventional vs. conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity. Int J Radiat Oncol Biol Phys. 1996 Feb 01; 34(3):555-64.
    View in: PubMed
    Score: 0.001
  134. The relationship of local control to distant metastasis in muscle invasive bladder cancer. J Urol. 1995 Dec; 154(6):2059-63; discussion 2063-4.
    View in: PubMed
    Score: 0.001
  135. Local control of muscle-invasive bladder cancer: preoperative radiotherapy and cystectomy versus cystectomy alone. Int J Radiat Oncol Biol Phys. 1995 May 15; 32(2):331-40.
    View in: PubMed
    Score: 0.001
  136. Radiotherapy and androgen ablation for clinically localized high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 1995 Apr 30; 32(1):13-20.
    View in: PubMed
    Score: 0.001
  137. Frequency and characterization of p53 mutations in clinically localized prostate cancer. Urology. 1995 Mar; 45(3):470-5.
    View in: PubMed
    Score: 0.001
  138. Local treatment for prostate cancer: 90 years later--response to M. V. Pilepich. Int J Radiat Oncol Biol Phys. 1995 Jan 15; 31(2):436.
    View in: PubMed
    Score: 0.001
  139. Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy. Urology. 1994 Dec; 44(6):869-75.
    View in: PubMed
    Score: 0.001
  140. Preoperative radiotherapy for muscle-invasive bladder carcinoma. Long term follow-up and prognostic factors for 338 patients. Cancer. 1994 Nov 15; 74(10):2819-27.
    View in: PubMed
    Score: 0.001
  141. Relationship of tumor DNA-ploidy to serum prostate-specific antigen doubling time after radiotherapy for prostate cancer. Urology. 1994 Nov; 44(5):711-8.
    View in: PubMed
    Score: 0.001
  142. Treatment related sequelae following external beam radiation for prostate cancer: a review with an update in patients with stages T1 and T2 tumor. J Urol. 1994 Nov; 152(5 Pt 2):1799-805.
    View in: PubMed
    Score: 0.001
  143. Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications. Int J Radiat Oncol Biol Phys. 1994 Sep 30; 30(2):279-87.
    View in: PubMed
    Score: 0.001
  144. Influence of initial presentation on treatment outcome of clinically localized prostate cancer treated by definitive radiation therapy. Int J Radiat Oncol Biol Phys. 1994 Sep 30; 30(2):331-7.
    View in: PubMed
    Score: 0.001
  145. Muscle-invasive bladder cancer treated with external beam radiotherapy: prognostic factors. Int J Radiat Oncol Biol Phys. 1994 Sep 30; 30(2):267-77.
    View in: PubMed
    Score: 0.001
  146. Serum prostate-specific antigen, clinical stage, pathologic grade, and the incidence of nodal metastases in prostate cancer. Urology. 1994 Aug; 44(2):215-20.
    View in: PubMed
    Score: 0.001
  147. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer. 1994 Jul 15; 74(2):670-8.
    View in: PubMed
    Score: 0.001
  148. Allogeneic bone marrow transplantation for leukemia following piperazinedione and fractionated total body irradiation. Am J Hematol. 1994 Jun; 46(2):82-6.
    View in: PubMed
    Score: 0.001
  149. Near-diploidy: a new prognostic factor for clinically localized prostate cancer treated with external beam radiation therapy. Cancer. 1994 Apr 01; 73(7):1895-903.
    View in: PubMed
    Score: 0.001
  150. Dedifferentiation of locally recurrent prostate cancer after radiation therapy. Evidence for tumor progression. Cancer. 1993 Jun 01; 71(11):3783-7.
    View in: PubMed
    Score: 0.001
  151. Complications following external beam radiation therapy for prostate cancer: an analysis of patients treated with and without staging pelvic lymphadenectomy. J Urol. 1991 Sep; 146(3):798-802.
    View in: PubMed
    Score: 0.001
  152. Conservative surgery and radiation therapy for soft tissue sarcoma of the wrist, hand, ankle, and foot. Cancer. 1990 Dec 15; 66(12):2482-91.
    View in: PubMed
    Score: 0.001
  153. The role of serum prostatic acid phosphatase in the management of adenocarcinoma of the prostate with radiotherapy. Int J Radiat Oncol Biol Phys. 1990 Dec; 19(6):1383-8.
    View in: PubMed
    Score: 0.001
  154. Radiation therapy of stage C prostate cancer: significance of Gleason grade to survival. Semin Urol. 1990 Nov; 8(4):225-31.
    View in: PubMed
    Score: 0.001
  155. Desmoid tumors: a 20-year radiotherapy experience. Int J Radiat Oncol Biol Phys. 1990 Jul; 19(1):37-40.
    View in: PubMed
    Score: 0.001
  156. Methylprednisolone, cyclosporine and methotrexate for prophylaxis of acute graft-versus-host disease. Bone Marrow Transplant. 1990 Apr; 5(4):269-72.
    View in: PubMed
    Score: 0.001
  157. Piperazinedione, total body irradiation, and autologous bone marrow transplantation in chronic myelogenous leukemia. J Clin Oncol. 1986 Jun; 4(6):906-11.
    View in: PubMed
    Score: 0.001
  158. High-dose melphalan and total body irradiation with bone marrow transplantation for refractory malignancies. Eur J Cancer Clin Oncol. 1986 Jun; 22(6):677-84.
    View in: PubMed
    Score: 0.001
  159. Systemic hemibody irradiation for overt and occult metastases. Cancer. 1985 May 01; 55(9 Suppl):2210-21.
    View in: PubMed
    Score: 0.000
  160. Single-dose half-body irradiation for the palliation of multiple bone metastases from solid tumors: a preliminary report. Int J Radiat Oncol Biol Phys. 1981 Jun; 7(6):773-81.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.